Objective: Excess mortality has been demonstrated in patients with SLE compared with the general population. We aimed to investigate the 5-year and 10-year all-cause mortality in patients with SLE compared with the general population in recent decades.
Methods: This was a Danish nationwide population-based exposure-matched cohort study. Incident cases of SLE diagnosed between 1996 and 2015 were identified using administrative health registries and followed until 2020, allowing for 5 and 10 years of follow-up. Patients with SLE were matched 1:5 on age and sex with individuals from the Danish general population. Time-to-event analyses were performed using the pseudo-observation approach.
Results: In total, 1351 incident cases of SLE and 6755 matched controls were identified. The crude risk difference (RD) for 5-year mortality decreased over the study period, from 10.3% (95% CI 6.5-14.1%) to 4.6% (95% CI 1.4-7.8%) for patients with SLE compared with controls. The relative risk (RR) for 5-year mortality decreased similarly in the same period. Adjustment for comorbidities revealed lower RD and RR for mortality in patients with SLE compared with controls, but the decreasing trend remained. The crude and adjusted RD and RR for 10-year mortality did not change over the calendar period. The 10-year RR was highest in young patients with SLE (<50 years of age).
Conclusion: The 5-year mortality risk decreased over time for both patients with SLE and matched controls. However, excess 5-year mortality for patients with SLE in the most recent calendar period and excess mortality late in their disease course remained. Continued focus on preventing disease progression and comorbidity is required.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1093/rheumatology/keae244 | DOI Listing |
Cureus
November 2024
Rheumatology, King Saud Medical City, Riyadh, SAU.
Background Systemic lupus erythematosus (SLE) is a chronic autoimmune disease associated with increased cardiovascular risk, partly due to dyslipidemia. This study aimed to evaluate the lipid profiles of Saudi Arabian patients with SLE and examine the impact of hydroxychloroquine (HCQ) and steroid use on these profiles, with a particular focus on patients with lupus nephritis. Methods A retrospective observational study was conducted at King Saud Medical City, Riyadh, Saudi Arabia, including SLE patients treated at the hospital's rheumatology clinic between July 2023 and December 2023.
View Article and Find Full Text PDFFront Pharmacol
December 2024
Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Taiyuan, China.
CAR-T cell therapy, a cutting-edge cellular immunotherapy with demonstrated efficacy in treating hematologic malignancies, also exhibits significant promise for addressing autoimmune diseases. This innovative therapeutic approach holds promise for achieving long-term remission in autoimmune diseases, potentially offering significant benefits to affected patients. Current targets under investigation for the treatment of these conditions include CD19, CD20, and BCMA, among others.
View Article and Find Full Text PDFTurk J Med Sci
December 2024
Division of Rheumatology, Department of Pediatrics, Faculty of Medicine, Hacettepe University, Ankara, Turkiye.
Background/aim: The transition from pediatric to adult-oriented care for individuals with juvenile-onset systemic lupus erythematosus (SLE) poses significant challenges. This study aimed to assess the outcomes of transitioning patients with juvenile-onset SLE from pediatric to adult-oriented care.
Materials And Methods: Patients with juvenile-onset SLE were included in the study.
Int Immunopharmacol
December 2024
Department of Rheumatology and Immunology, Weifang People's Hospital, Shandong Second Medical University, Weifang 261000, Shandong, China; Medical Research Center, Weifang People's Hospital, Shandong Second Medical University, Weifang 261000, Shandong, China. Electronic address:
Interferon-inducible transmembrane (IFITM) family members (IFITM1, IFITM2, IFITM3) are extensively expressed in T cells and are involved in adaptive immunity. However, little is known about the expression of IFITM1, IFITM2 and IFITM3 in monocytes and their roles in systemic lupus erythematosus (SLE). Our study has shown that the expression of IFITM1, IFITM2, and IFITM3 in peripheral blood mononuclear cells (PBMCs) of SLE patients was dysregulated, and the expression of IFITM3 in SLE was significantly higher than that of healthy controls.
View Article and Find Full Text PDFRespir Res
December 2024
Department of Mechanical and Product Design Engineering, Swinburne University of Technology, Hawthorn, VIC, Australia.
By virtue of applying small tidal volumes, high-frequency ventilation is advocated as a method of minimizing ventilator-induced lung injury. Lung protective benefits are established in infants, but not in other patient cohorts. Efforts to improve and extend the lung protection potential should consider how fundamental modes of gas transport can be exploited to minimize harmful tidal volumes while maintaining or improving ventilation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!